Arbutus Biopharma Corp (ABUS) Operating margin 2016–2025
Arbutus Biopharma Corp (ABUS) operating margin by fiscal year — reported operating income divided by reported revenue.
-271.0%FY2025 · since FY2016: -32973.8% → -271.0%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -271.0% | +965.8 pp |
| FY2024 | -1236.7% | -806.2 pp |
| FY2023 | -430.5% | -262.8 pp |
| FY2022 | -167.8% | +501.4 pp |
| FY2021 | -669.1% | +167.0 pp |
| FY2020 | -836.1% | +1557.9 pp |
| FY2019 | -2394.0% | -883.8 pp |
| FY2018 | -1510.2% | -473.4 pp |
| FY2017 | -1036.7% | +31937.0 pp |
| FY2016 | -32973.8% | — |
Operating margin = reported operating income ÷ reported revenue for the same fiscal year. Operating-loss years show as a negative margin.
Source: SEC XBRL filings · For reference only · Not investment advice
More ABUS financial trends
ABUS RevenueABUS Net incomeABUS Net marginABUS Gross profitABUS Gross marginABUS Operating incomeABUS Operating cash flowABUS Free cash flowABUS Capital expendituresABUS Return on equityABUS Stock buybacksABUS Dividends paidABUS Total assetsABUS Total liabilitiesABUS Shareholders’ equityABUS overview →